The global heart failure POC & LOC devices market size is
expected to reach USD 129.69 million by 2025 and is projected to grow at a CAGR
of 16.2%, according to a new report by Grand View Research, Inc. A paradigm
shift in diagnostic sectors from late-stage disease detection to early
identification of diseases as a viable strategy to curb rising healthcare costs
has driven the market. This shift has led to the development of disposable and
low-cost LOC devices that integrate various sensors and associated accessories
in a single space for detection of the cardiac biomarkers from a single
specimen to evaluate the risk of having a heart attack.
Furthermore, the
development of predictive modeling techniques-based decision support software
to analyze the data measured by the LOC assays to enable therapy monitoring is
one of the key market drivers. Also, ongoing studies on the application of
saliva-based nano-biochip tests for measuring myocardial infarction is driving
organic revenue growth.
POC testing exhibits
potential savings across various settings, including hospitals, general
practice, and remote areas. In the U.S., the employment of POC devices resulted
in a 20% decrease in hospital admissions to the chest pain unit, resulting in
substantial savings in time and costs.
In the cardiac
observation unit (U.S.), the implementation of POC troponin testing helped
reduce hospital stays, decrease admission rates, and remove the need for
multiple costly procedures, resulting in 25% cost saving per patient.
Furthermore, the integration of smartphones and apps in POC diagnostics for
managing the cardiac health of an individual is one of the significant
innovations in Heart Failure POC & LOC Devices market.
Browse full research report on Heart Failure POC & LOC Devices Market: https://www.grandviewresearch.com/industry-analysis/heart-failure-poc-loc-devices-market
Further key findings from the report
suggest:
- Proteomic analysis includes products
that test protein markers, such as troponin, myoglobin, and Creatine
Kinase MB Isoenzyme (CK-MB)
- This segment accounted for the
leading revenue share, as most of the currently available products are
based on testing of protein markers
- Increasing implementation of
microfluidic LOC technology for assessing putative biomarkers has led to
the largest revenue share of this technology
- Microfluidic technologyhas been
implemented for various biological applications, such as
immunohybridization techniques, enzymatic assays, PCR, and others
- Clinics that include physician’s
office, pharmacy & retail clinics, urgent care clinics, and
non-practice clinics are the key revenue generating end-users
- A high usage rate of POC devices by
general practitioners for rapid investigation, deciding early treatment,
timely referral, and less uncertainty for patients has driven the revenue
growth through clinics
- The U.S. dominated the global Heart
Failure POC & LOC devices market owing to the presence of a substantial
number of primary care clinics that are deploying POC cardiac marker test
as a measure for early detection of heart failure
- Expanding urbanization and increasing
geriatric population underpin the demand for robust and improved
healthcare services such as POC diagnostics for routine cardiac health
monitoring in Asian countries
- Moreover, initiatives are undertaken
for training young healthcare personnel about POC cardiac troponin
T/cardiac troponin I biomarkers
- This, in turn, is anticipated to
result in the surging adoption rate of POC devices in Asian countries
- Abbott, Siemens Healthineers,
Danahar, and F. Hoffmann-La Roche Ltd are some key participants operating
in the space
- Companies are engaged in mergers and
acquisitions of emerging players. Acquisition of Alere by Abbott, Beckman
Coulter, Inc by Danahar, and Accriva Diagnostics by Instrumentation
Laboratory are some examples of acquisitions in this market
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/heart-failure-poc-loc-devices-market/request/rs1
Grand View Research has segmented the heart failure
POC & LOC devices market on the basis of test type, technology, end-use,
and regions:
- Proteomic
Testing
- Metabolomic
Testing
- Genomic
Testing
Technology Outlook (Revenue, USD Million,
2014 - 2025)
- Microfluidics
- Array-based
Systems
- Others
End-use Outlook (Revenue, USD Million,
2014 - 2025)
- Clinics
- Hospitals
- Home
- Assisted
Living Healthcare Facilities
- Laboratory
Regional Outlook (Revenue, USD Million,
2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Middle
East and Africa (MEA)
- South
Africa
- Saudi
Arabia
About
Grand View Research
Grand View Research, Inc.
is a U.S. based market research and consulting company, registered in the State
of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment